Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 174.45 2.56
Cipla Lt 557.40 8.38
Ong Corp 444.60 2.17
Tata Stl 519.20 1.10
Ntpc Ltd 140.10 1.74
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Matrix Laboratories Limited
Matrix Laboratories Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:24794NSE:MATRIXLABSBloomberg:HDPH@INReuters:MAXL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE604D01023
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
31-MAR-09 The company received the first tentative approval from the U.S Food and Drug Administration (FDA) under the President`s Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 200 mg/300 mg. 12-MAR-09 The company has received a tentative approval for Lopinavir / Ritonavir Tablets 200/50 mg from US Food & Drug Administration (USFDA) under the...   More..
Business Profile Future Plans
One To One
Recent news
Previous

 


Brief Financials (in Rs. Mn.) 
Period ending (months)30-Jun-2009(3)31-Mar-2009 (12)31-Mar-2008 (12)
Net sales 4055.5014790.309787.64
Other Income15.40218.50201.75
Total Income4070.9015008.809989.39
Cost of goods sold3623.9011745.208013.28
OPBDIT447.003263.601976.11
PAT165.601889.50-2983.57
Gross Block---
Equity capital312.70309.20309.18
EPS (Rs.)-12.22-19.32
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-3.93 - 16.66NA
Debt / Equity (x)---
Operating margin (% of OI)11.021.719.8
Net margin (% of OI) 4.112.6-29.9
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
1-1-151/1
Sairam Towers
IVth Floor, Alexander Road
Secunderabad
Andhra Pradesh-500 003
PHONE
(040) 2770 0363 / 361/ 347
FAX
(040) 2770 0343
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer